原发中枢神经系统弥漫大B细胞淋巴瘤23例临床分析(3)
[3] Brastianos P K,Batchelor T T.Primary central nervous system lymphoma: overview of current treatment strategies[J].Hematol Oncol Clin North Am,2012,26(4):897-916.
[4] Ferreri A J,Guerra E,Regazzi M,et al.Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.[J].Br J Cancer,2004,90(2):353-358.
[5] Taoka K,Okoshi Y,Sakamoto N,et al.A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma.[J].Int J Hematol,2010,92(4):617-623.
[6] Rubenstein J L,Combs D,Rosenberg J,et al.Rituximab therapy for CNS lymphomas:targeting the leptomeningeal compartment[J].Blood,2003,101:466-468.
[7] Birnbaum T,Stadler E A,Von B L,et al.Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.[J].J Neurooncol,2012,109(2):285-291.
[8] Fritsch K,Kasenda B,Hader C,et al.Immunochemotherapy with rituximab, methotrexate, procarbazine,and lomustine for primary CNS lymphoma(PCNSL) in the elderly[J].Ann Oncol,2011,22(9):2080-2085.
[9] Holdhoff M,Ambady P,Abdelaziz A,et al.High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma[J].Neurology,2014,83(3):235-239.
[10] Doolittle N D,Dosa E,Fu R,et al.Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery[J].J Clin Oncol,2013,31(31):4026-4027.
[11]余海峰,范云,羅吕宏,等.洛铂联合依托泊苷与顺铂联合依托泊苷治疗初治小细胞肺癌的临床研究[J].中国肿瘤临床,2010,37(20):1184-1186,1189.
[12]陈珵,魏道林,王椿,等.含培门冬酶化疗方案拯救性治疗难治性淋巴瘤的效果观察[J].白血病·淋巴瘤,2014,23(10):611-615.
(收稿日期:2018-04-08), 百拇医药(吴荣娟 郑瑞玑)
[4] Ferreri A J,Guerra E,Regazzi M,et al.Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.[J].Br J Cancer,2004,90(2):353-358.
[5] Taoka K,Okoshi Y,Sakamoto N,et al.A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma.[J].Int J Hematol,2010,92(4):617-623.
[6] Rubenstein J L,Combs D,Rosenberg J,et al.Rituximab therapy for CNS lymphomas:targeting the leptomeningeal compartment[J].Blood,2003,101:466-468.
[7] Birnbaum T,Stadler E A,Von B L,et al.Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.[J].J Neurooncol,2012,109(2):285-291.
[8] Fritsch K,Kasenda B,Hader C,et al.Immunochemotherapy with rituximab, methotrexate, procarbazine,and lomustine for primary CNS lymphoma(PCNSL) in the elderly[J].Ann Oncol,2011,22(9):2080-2085.
[9] Holdhoff M,Ambady P,Abdelaziz A,et al.High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma[J].Neurology,2014,83(3):235-239.
[10] Doolittle N D,Dosa E,Fu R,et al.Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery[J].J Clin Oncol,2013,31(31):4026-4027.
[11]余海峰,范云,羅吕宏,等.洛铂联合依托泊苷与顺铂联合依托泊苷治疗初治小细胞肺癌的临床研究[J].中国肿瘤临床,2010,37(20):1184-1186,1189.
[12]陈珵,魏道林,王椿,等.含培门冬酶化疗方案拯救性治疗难治性淋巴瘤的效果观察[J].白血病·淋巴瘤,2014,23(10):611-615.
(收稿日期:2018-04-08), 百拇医药(吴荣娟 郑瑞玑)